Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01619683 · ClinicalTrials.gov registry record · Phase 3

Assessment of the Effects of Enclomiphene Citrate on Bone Mineral Density in Men With Secondary Hypogonadism

A Phase 3 study, sponsored by Repros Therapeutics.

Completed
Registry status
Phase 3
Development phase
300
Enrollment target

NCT01619683: Completed Phase 3 study, sponsored by Repros Therapeutics.

NCT01619683 is a Phase 3 study that has completed, run by Repros Therapeutics. The registered enrollment target is 300 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01619683, a Phase 3 study, has completed, sponsored by Repros Therapeutics.

COMPLETED
Registry status
Phase 3
Development phase
300 participants
Enrollment target

Study Summary

To determine the effects of 12 months of treatment with Androxal on bone mineral density in men with secondary hypogonadism.

Primary Outcome

Change in bome mineral density at the end of study compared to placebo

Interventions

  • DRUG Placebo
  • DRUG enclomiphene citrate

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2012-09
Est. Completion 2014-09
Phase Phase 3
Repros Therapeutics

50 total trials

What the finished NCT01619683 record still lists

NCT01619683 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01619683 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01619683 about?

NCT01619683 is a clinical study titled "Assessment of the Effects of Enclomiphene Citrate on Bone Mineral Density in Men With Secondary Hypogonadism". To determine the effects of 12 months of treatment with Androxal on bone mineral density in men with secondary hypogonadism.

What is the current status of trial NCT01619683?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2012-09. Estimated completion is 2014-09.

What interventions are being tested in trial NCT01619683?

The interventions under investigation include: Placebo (DRUG), enclomiphene citrate (DRUG).

Who is sponsoring clinical trial NCT01619683?

This trial is sponsored by Repros Therapeutics, which has 50 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01619683's enrollment target sits among peer trials

300 1122nd of 2000 higher than 840 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01619683, the US trial registry maintained by the National Library of Medicine. NCT01619683 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.